INCREASING PATIENT SAFETY BY PERMITTING GENERIC DRUG MANUFACTURERS TO UPDATE PRODUCT SAFETY LABELS

Jessica L. Seiden*

I. INTRODUCTION ...................................................................... 412
II. BACKGROUND/OVERVIEW ..................................................... 414
   A. Statutory Background .............................................. 414
   B. The 2012 Enactment of FDASIA/GDUFA: Paving the Way for Generic Label Updating .................. 417
   C. Recent Supreme Court Cases .................................. 419
   D. Proposed FDA Regulation ...................................... 423
III. REEXAMINING THE CURRENT FDA REGULATIONS TO PERMIT GENERIC DRUG MANUFACTURERS TO UPDATE SAFETY LABELS ................................................................. 424
   A. Public Policy Favors Informing Patients and Physicians of Changes in Drug Safety Information ............................................................... 425
   B. Generic Drugs Will Continue to be an Affordable Alternative to Brand-Name Prescriptions .......... 429
   C. Allowing Generic Drug Makers to Update Product Safety Labels will Provide a Means for Generic Drugs which no Longer have a Brand-name Counterpart to Make Safety Updates ............................................. 431
IV. CONCLUSION ...................................................................... 432

* J.D. Candidate, 2016, Seton Hall University School of Law.
I. INTRODUCTION

Since 1984, the Food and Drug Administration (“FDA”) has approved over 8,000 generic drugs, which comprise approximately seventy-eight percent of currently filled prescriptions.¹ The Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) governs the approval of generic drugs.² The Act provides an expedited approval process for generic drugs that have an identical Reference Listed Drug (“RLD”). Provided a generic drug is the “same” as its listed drug counterpart, its manufacturer is permitted to forgo clinical testing, on the condition that the drug maintains the same label as the listed drug.³ “Sameness” requires the generic drug be the same as the brand-name drug in “dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.”⁴ Generic drug manufacturers have no authority to modify or update their own safety labels if they want to maintain their generic approval.⁵ The inability to independently update labels has led to issues concerning generic drug manufacturers’ liability for failure to warn of safety concerns, which have recently been addressed by the U.S. Supreme Court.⁶

Congress began to combat these concerns with the enactment of the Generic Drug User Fee Amendments of 2012 (“GDUFA”).⁷ The GDUFA recognizes the growth of the generic drug industry by expediting the approval process for generics, saving time and money

---

⁴ Id.
⁵ Id.
for the industry, and ensuring Americans have access to low cost, quality medicine. In exchange for faster approval times, the generic industry must pay user fees, as branded pharmaceutical drugs are required to do. The GDUFA may be considered the beginning of major reform for the generic drug industry, placing some of the same obligations and benefits on the generic industry that the brand-name manufacturers have dealt with for years.

The growth of the generic industry and the issues presented in recent Supreme Court cases have prompted the FDA to reconsider the current federal mandate and to suggest that generic drug manufacturers be permitted to update safety labels in response to safety issues that have been discovered. The proposed regulation would require generic drug makers to update their labels in light of newly acquired safety information to avoid injury to consumers, which could result in legal liability. This Note argues that allowing generic drug makers to update safety labels as soon as new information is received will increase patient safety and prevent injuries by providing timely updates to safety information. This would also allow generic drugs that no longer have a brand-name counterpart to update their labels.

These changes may also have an impact on manufacturer’s exposure to failure-to-warn liability. Under the Supreme Court’s 2011 ruling in PLIVA v. Mensing, generic drug makers are unable to add new side effect and safety information to product labeling and therefore should not be held accountable for any failure-to-warn claims. Currently, access to the courts depends on whether an individual has been prescribed a brand-name or generic drug. Dr.
Janet Woodcock, Director of the Center for Drug Evaluation and Research at the Food and Drug Administration stated that if the proposed regulatory change is approved, it would allow consumers to file failure-to-warn claims against generic drug manufacturers.\textsuperscript{16} Once generic drug makers have the right to change their label, they would be responsible for knowing the full effects of the drugs they produce, and may be sued for failing to update their labels in a timely fashion.\textsuperscript{17} The FDA notice of the proposed rule acknowledges that the proposed regulation may also change generic drug manufacturer’s liability.\textsuperscript{18} Although the proposed regulations may have a significant impact on generic drug makers’ liability, such discussion is beyond the scope of this Note.

Part II of this Note will introduce background legislation and regulations concerning the labeling of brand-name and generic drugs. It will describe the subsequent amendments to food and drug legislation in response to the growth of generic drugs over the past few decades. Part II will also introduce the 2013 proposed regulatory amendments, which would provide generic manufacturers the ability to independently update safety labels. Part III of this Note will discuss the benefits of independent label changes to public policy and patient safety while keeping costs significantly lower than brand-name counterparts.

\section*{II. BACKGROUND/OVERVIEW}

\textbf{A. Statutory Background}

The Federal Food, Drug, and Cosmetic Act ("FDCA") and the Public Health Service Act ("PHSA"). \text{"[p]rovide [the] FDA with authority over the labeling for drugs and biological products."}\textsuperscript{19} The Acts also authorize the FDA to "enact regulations to facilitate the review and approval of applications regarding the labeling for those products."\textsuperscript{20} Section 502(f) of the FDCA states that "a product is misbranded unless its labeling bears adequate directions for use, including adequate warnings against, among other things, unsafe dosage, methods, duration of administration, or application."\textsuperscript{21}

\textsuperscript{16} Id.
\textsuperscript{17} Carlson, \textit{supra} note 10.
\textsuperscript{19} \textit{See} 21 U.S.C. \textsection 301 (2016); \textit{see also} 42 U.S.C. \textsection 201 (2016).
\textsuperscript{20} Woodcock, \textit{supra} note 15.
\textsuperscript{21} Woodcock, \textit{supra} note 15.
According to Section 502(j) of the FDCA, “a product is misbranded if it is dangerous to health when used in the manner prescribed, recommended, or suggested in its labeling.” These statutory provisions created new standards for drug manufacturer’s products and facilities.

In 1984, the FDCA was amended to include the Drug Competition and Patent Term Restoration Act, more commonly known as The Hatch-Waxman Act. The Hatch-Waxman Act provided a less stringent approval process for generic drug makers. The generic manufacturer is now required to submit an abbreviated new drug application, showing the generic drug is the “same” as a previously approved brand-name drug, and the generic is “bioequivalent” to the brand-name drug. Under the “sameness” requirement, the generic manufacturer must show that the generic drug meets the same standards of safety and efficacy, by proving that the generic drug has the same active ingredient, is identical in strength, dosage and administration, and has the same safety label. The Hatch-Waxman Act exempted generic manufacturers from the “expensive, time-consuming, and ultimately repetitive clinical testing and trials that already had been performed on the innovator drug.” In the twenty-two years preceding the Act, only fifteen generics had been approved by the FDA. One year after the Act, more than 1,000 drugs were submitted for approval to the FDA. Hatch-Waxman has resulted in billions of dollars of savings to the health care industry and consumers.

Currently, for most substantive changes to drug labeling, a brand-name manufacturer must submit an approval supplement and obtain FDA approval of the proposed labeling modification. FDA regulations also require manufacturers of pharmaceutical and biological products to submit reports of adverse drug experiences

22 Woodcock, supra note 15.
24 Id.
25 Neas, supra note 3.
26 Neas, supra note 3.
27 Neas, supra note 3.
28 Neas, supra note 3.
29 Neas, supra note 3.
that occur after approval.\textsuperscript{31} In the interest of public health, the FDCA permits certain labeling changes based on newly acquired safety information about the drug when the manufacturer submits a “changes being effected” (“CBE-0”) supplement describing the change.\textsuperscript{32} Newly acquired safety information is defined by the FDCA as, “. . .information derived from a clinical trial, an adverse event report, a post approval study . . . peer reviewed biomedical literature, data derived from the post-market risk identification and analysis system under section 505(k); or other scientific data deemed appropriate by [the FDA].”\textsuperscript{33} When this information is received, the brand drug must update their warnings labels to reflect the new information.\textsuperscript{34}

The CBE-0 supplement regulations, “. . .allow application holders to comply with the requirement to update labeling promptly to include a warning about a clinically significant hazard as soon as there is reasonable evidence of a causal association with a drug . . . .”\textsuperscript{35} According to the 2008 amended regulations governing the CBE-0 process, a CBE-0 labeling supplement is only appropriate to show new information.\textsuperscript{36} The 2008 amendments clarified that the supplement may be used to “add or strengthen a contraindication, warning, precaution, or adverse reaction only if there is sufficient evidence of a causal association with the approved product.”\textsuperscript{37} The FDA reviews all labeling changes proposed in a CBE-0 supplement and the underlying data and research supporting the change.\textsuperscript{38} The FDA then accepts, rejects, or requests modifications to the proposed changes as deemed appropriate, and can bring enforcement action if the information makes the product’s label false or misleading.\textsuperscript{39} If the newly acquired information brings to light that the product no longer meets FDA standards, the agency may choose to rescind the drug’s approval.\textsuperscript{40}

\textsuperscript{31} Id.
\textsuperscript{32} Id.; See also 21 C.F.R. § 314.70(c) (6) (iii); 21 C.F.R. § 601.12(f) (1).
\textsuperscript{34} See 21 U.S.C. § 505(o) (2) (C).
\textsuperscript{35} See 78 Fed. Register 67985; see also 21 C.F.R. § 201.57(c).
\textsuperscript{37} Id.
\textsuperscript{38} Id.
\textsuperscript{39} See 21 U.S.C. § 352(a).
\textsuperscript{40} See 21 U.S.C. §§ 355(e), 355-1.
B. The 2012 Enactment of FDASIA/GDUFA: Paving the Way for Generic Label Updating

In 2010, seventy-eight percent of pharmaceutical prescriptions were filled with generic brands. Over the past decade, generic drugs have provided a savings of over $824 billion dollars to the nation’s health care system. In response to the rapid growth of generic drugs over the past decades, Congress, in 2012, enacted the Generic Drug User Fee Act (“GDUFA”) as a part of the Food and Drugs Administration Safety and Innovation Act (“FDASIA”). GDUFA allows for more speed in approving generic drugs while ensuring safety and low costs by requiring generic manufacturers to pay fees to supplement the costs of reviewing generic drug applications and inspecting facilities. As the FDA has explained, “[r]ecognizing the critical role generic drugs play in providing more affordable, therapeutically equivalent medicine, the Generic Drug User Fee program is designed to keep individual fee amounts as low as possible to supplement appropriated funding to ensure that consumers continue to receive the significant benefits offered by generic drugs.”

The FDASIA gives the FDA the authority to collect user fees from the pharmaceutical industry to “fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biological products.” The FDASIA also encourages innovation by providing a “breakthrough therapy” designation for certain drugs that may be

---


44 Fact Sheet, supra note 1.


46 Generic Drug User Fee Act Program Performance Goals and Procedures, supra note 43.

This designation would allow for an expedited review and approval process through the collection of fees to create additional resources. The FDASIA protects the drug supply chain and ensures patients have access to drugs they need by extending the FDA’s detention authority and increasing penalties for adulterated and counterfeit drugs.

The purpose of the GDUFA is to increase safety by requiring that any manufacturer who participates in the U.S. generic drug industry is inspected biennially. It also will “deliver greater predictability and timeliness to the review of generic drug applications, slashing review times and saving industry time and money.” The GDUFA also requires that any domestic or international facility involved in the manufacture of generic drugs and their ingredients be identified upon their sale in the United States to increase transparency in the complex, global pharmaceutical market. All facilities and companies selling generic drugs must register annually with the FDA. This includes manufacturers of active pharmaceutical ingredients whose products may be used in US products through another manufacturer or facility that repackage generic drugs. The FDA has laid out guidance on which companies need to self-identify and what information they are required to provide to the FDA. In its guidance documents, the FDA explained that “[t]he information provided through self-identification will enable quick, accurate and reliable surveillance of generic drugs and facilitate inspections and compliance.”

The GDUFA also aims to cut down the review time of generic drug applications from thirty-one months to about ten months.

---

48 Id.
49 Id.
50 Id.
51 Generic Drug User Fee Act Program Performance Goals and Procedures, supra note 43.
52 Fact Sheet, supra note 1.
53 Fact Sheet, supra note 1.
55 Id.
56 Id.
57 Id.
58 Thomas Sullivan, The Food and Drug Administration Safety and Innovation Act
The funds collected from the user fees, which is stated to be one half of one percent of generic drug sales, will be used to assess the safety of generic drugs.\textsuperscript{59}

The user fees result in benefits to the public health by financing the FDA to carry out functions that it could not do previously.\textsuperscript{60} By cutting the review time of a generic drug application, the GDUFA will increase savings in development time, while decreasing the costs of bringing a generic drug to the market.\textsuperscript{61} Therefore, this may also result in a decline in costs to consumers.\textsuperscript{62}

\section*{C. Recent Supreme Court Cases}

Recent Supreme Court cases have addressed the issue of whether generic drug manufacturers should be liable for failing to provide adequate warnings on drug labels.\textsuperscript{63} This wave of lawsuits began with \textit{Wyeth v. Levine} in 2009.\textsuperscript{64}

In \textit{Wyeth}, the patient was injured by using a brand-name anti-nausea drug through an IV-push method.\textsuperscript{65} The patient claimed the drug’s label was defective because it failed to instruct clinicians to use an IV-drip method, rather than the higher-risk push method.\textsuperscript{66} The patient filed a failure-to-warn suit in state court against the drug manufacturer, Wyeth, for failing to update the product’s label with newly acquired safety information, even though the labels conformed to FDA regulations.\textsuperscript{67}

The Supreme Court determined that federal law does not preempt a state law failure to warn claim that a brand-name drug’s


\footnotesize{\textsuperscript{59} Id.}

\footnotesize{\textsuperscript{60} Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.}

\footnotesize{\textsuperscript{61} Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.}

\footnotesize{\textsuperscript{62} Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.}

\footnotesize{\textsuperscript{63} Woodcock, supra note 15.}

\footnotesize{\textsuperscript{64} \textit{Wyeth v. Levine}, 555 U.S. 555 (2009).}

\footnotesize{\textsuperscript{65} See \textit{Wyeth}, 555 U.S. at 559; see also Marie Boyd, \textit{Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs}, 35 CARDOZO L. REV. 1525, 1530 (2014).}

\footnotesize{\textsuperscript{66} Id.}

label did not contain an adequate warning. The Court explained that “[i]t has remained a central premise of federal drug regulation that the manufacturer bears responsibility for the contents of its label at all times.” The court held that the manufacturer must create an adequate safety label and ensure it is up to date as long as the product is being sold. The Court opined “Wyeth failed to demonstrate that it was impossible for it to comply with both federal and state requirements . . . the mere fact that the FDA approved . . . [the] label does not establish that it would have prohibited such a change.” The Court held that Wyeth could have strengthened the warning labels under the FDA’s CBE-0 regulation to comply with state law. The Court’s holding in Wyeth sent a clear message to brand-name drug manufacturers that “if they do not unilaterally strengthen their labels when they know it is necessary, they will face liability in the state court system.”

In 2011, the Supreme Court distinguished Wyeth in the subsequent case PLIVA Inc. v. Mensing. In PLIVA, the patients alleged they developed tardive dyskinesia after using the generic drug metoclopramide. The patients claimed the generic drug label did not contain adequate warnings of this adverse side effect. The manufacturer of the drug argued that: “(1) FDA regulations require the warnings on generic pharmaceuticals to be the same as those of the brand-name product; and (2) they had no ability to unilaterally add or strengthen warnings without FDA approval.” The Court agreed with the manufacturer and held the claim was preempted because generic manufacturers cannot add further warnings without violating FDA regulations under the Hatch-Waxman Act.

---

68 Woodcock, supra note 15.
69 Wyeth, 555 U.S. at 570-71.
70 Id.
71 Wyeth, 555 U.S. at 573.
72 Boyd, supra note 65, at 1530.
74 PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 at 2581.
75 Id. at 2573.
77 Rose et al., supra note 76.
78 Rose et al., supra note 76.
The holdings in Wyeth and PLIVA suggest “the Supreme Court has determined that generic manufacturer’s lack of independence with respect to drug safety labeling makes it impossible for them to comply with both Federal drug labeling requirements, and state tort law (failure-to-warn or design-defect) requirements.”\textsuperscript{79} The Supreme Court’s holdings in both cases suggests that access to the courts depends on whether a consumer purchased a generic or a brand-name drug.\textsuperscript{80}

In 2013, the Supreme Court decided Mutual Pharmaceutical Co. \textit{v.} Bartlett.\textsuperscript{81} In \textit{Bartlett}, the plaintiff suffered an adverse effect from taking the generic medication Sundilac.\textsuperscript{82} The patient, who took the prescribed medication to alleviate muscle pain, developed Stevens-Johnson syndrome and toxic epidermal necrolysis and became disfigured as a result.\textsuperscript{83} This side effect was originally listed as “a possible adverse reaction” on the safety label and was later moved to the “warnings” section of the generic label in conformance with the FDA’s recommendation.\textsuperscript{84}

The Supreme Court held in \textit{Bartlett} that federal law preempts a state-law design-defect claim against a generic drug manufacturer under \textit{PLIVA}.\textsuperscript{85} The Court first decided that New Hampshire does not have a “pure” design-defect cause of action, which would require a jury to balance the risks and benefits of an FDA approved drug to determine if it is “unreasonably dangerous.”\textsuperscript{86} As the FDA argued in its brief, this would undermine their assurance of approved drugs on a state-by-state and case-by-case basis, as well as Congress’ purpose that FDA approvals are made by experts applying science based judgment.\textsuperscript{87} The Supreme Court determined that New Hampshire’s design-defect cause of action includes an evaluation of the adequacy of the label.\textsuperscript{88} Through the design-defect analysis, the Court determined that generic drug manufacturers should not be held accountable for failure-to-warn or design-defect claims because generic drug makers are not permitted to independently update

\textsuperscript{79} Thomas, \textit{supra} note 6.

\textsuperscript{80} Woodcock, \textit{supra} note 15.

\textsuperscript{81} \textit{See} Bartlett, 133 S. Ct. at 2494.

\textsuperscript{82} \textit{Id.} at 2472.

\textsuperscript{83} \textit{Id.}

\textsuperscript{84} Wolfman, \textit{supra} note 23.

\textsuperscript{85} Bartlett, 133 S. Ct. at 2476; Wolfman, \textit{supra} note 23.

\textsuperscript{86} Bartlett, 133 S. Ct. at 2470.

\textsuperscript{87} \textit{Id.}; Brief for the United States as Amicus Curiae at 25, \textit{Mutual Pharm. Co. \textit{v.} Bartlett}, 133 S. Ct. 2466 (2013).

\textsuperscript{88} \textit{See} Bartlett, 133 S. Ct. at 2470.
safety information on drug labeling. 89

Recently, a case has been decided by California’s highest court that contests the issue of generic drug liability. 90 Here, the plaintiff was injured from her prolonged use of a generic form of Fosamax. 91 She claimed that Teva, the generic manufacturer, failed to update their warnings in compliance with the brand Fosamax’s warnings. 92 The defense rebutted that the plaintiff’s claim was preempted by PLIVA. The trial court held, and the appellate court affirmed, that since the brand-name drug maker made the safety update, the generics were at fault for failing to immediately update their labels to conform to the newly acquired information. 93 This case raised issues about the scope of PLIVA and whether failure-to-update claims would be preempted by federal law. 94 The California Supreme Court declined to review the decision, therefore the pharmaceutical company appealed to the United States Supreme Court. 95 The subsequent petition was denied, leaving the decision about generic drug liability to the FDA. 96 The Supreme Court’s denial of the petition to hear this case may pave the way for similar failure to warn claims to be brought against generic drug makers in state court. 97

Similarly, the Alabama Supreme Court recently upheld a suit against brand-name manufacturer for damages caused by the generic form under the concept of “innovator liability.” 98 Here, the court found brand drugs could be liable because the generic manufacturers relied on the warnings and labels of the brand drug. 99

91 Id. at 101.
93 Id.
94 Id.
95 Id.
96 Id.; see Teva Pharm. USA, Inc. v. Superior Court, 135 S.Ct. 831 (2015).
The court relied on the holding in *PLIVA*, finding that the federal regulatory scheme made it foreseeable that the brand-name drug owed the generic version a duty of care. The pharmaceutical industry fears that this precedent could cause a damaging trend throughout the U.S. economy.

**D. Proposed FDA Regulation**

Under the current federal regulations, a generic drug manufacturer may only use the CBE-0 supplement process to update its product labeling to conform to the approved safety label for the similar brand-name drug. A generic drug manufacturer may not independently file a CBE-0 supplement to the FDA in light of newly acquired safety information, nor unilaterally change its product’s label to add information that is different from the brand-name drug’s label.

On November 13, 2013, the FDA proposed to add 21 C.F.R. 314.70(c)(8), which amends the current regulations and procedures that govern the ability to update and change generic drug safety labels. This proposed rule would allow generic drug manufacturers to independently submit “changes being effected” (“CBE-0”) supplements to update labels in light of newly acquired safety information, regardless of whether this information may differ from the warnings on the brand-name drug. The generic manufacturer would be able to distribute updated safety labels after submitting a CBE-0 to the FDA, as well as safety information supporting the change. The CBE-0 will also notify the maker of the listed drug of the newly acquired safety information.

To make updated safety information readily available to the public and to avoid confusion, the FDA proposed establishing a webpage where the FDA will post new safety information acquired from the CBE-0 supplements.
This proposed rule would allow a generic drug to display a label that is temporarily inconsistent with the labels of the listed drug. The FDA would then evaluate whether the change is justified and make a decision on the generic and listed drug change at the same time, and as a result, both drugs will have the same FDA approved label. After the FDA approves the safety label change, there will be a thirty day time frame in which all drug manufacturers of the “same” drug will have to submit a CBE-0 supplement with conforming label changes.

The amended regulations would also permit generic drugs which no longer have a brand-name counterpart to update their own labels. Under current regulations, there is no technique to accomplish such label change, and therefore, these drugs are being sold on the market with potentially incorrect or out-of-date safety information. The FDA estimates approximately 420 drugs are sold only in the generic form, and the listed drug is no longer manufactured. Current FDA regulations also prohibit a generic drug manufacturer from sending a “Dear Doctor” letter which would inform physicians of updated and new safety warning information. The FDA views “Dear Doctor” letters as labeling, therefore a generic is not permitted to send such letter with new safety information that is different from the brand name label.

III. REEXAMINING THE CURRENT FDA REGULATIONS TO PERMIT GENERIC DRUG MANUFACTURERS TO UPDATE SAFETY LABELS

FDA-approved drug labeling provides patients with essential information needed for the safe and effective use of a drug. Further, approved labels reflect the FDA’s findings of the safety and effectiveness under the labeled conditions of use. Scholars argue that “[t]he primary purpose of labeling for prescription drugs is to

109 Id.
111 Woodcock, supra note 15.
112 Carlson, supra note 10.
113 Carlson, supra note 10.
115 Boyd, supra note 65 at 1536.
116 Id.
117 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.
provide health care practitioners with the essential scientific information needed to facilitate prescribing decisions, thereby enhancing the safe and effective use of prescription drug products and reducing the likelihood of medication errors.¹¹⁸ This safety information is used by practitioners and patients to make decisions about prescription drugs by weighing the stated risks against the benefits.¹¹⁹

As of 2010, nearly 90% of pharmaceuticals in the United States are filled with a generic brand despite the availability of a substitute.¹²⁰ Despite the changes in the market, and the evolution of the generic drug industry, the regulations concerning generic labeling have remained largely unchanged.¹²¹

Generic drug makers may not always be able to quickly inform consumers of updated safety information, because they are not able to act under the same authority as their brand-name counterparts.¹²² Generic drugs must maintain an identical label to their brand-name substitutes, and are only required to update safety labels when the brand-name has filed a CBE Supplement with the FDA and the change has been approved.¹²³

A. Public Policy Favors Informing Patients and Physicians of Changes in Drug Safety Information

The side effects and risks of taking a particular drug may not come to light until after the drug has been approved by the FDA.¹²⁴ Therefore, both brand-name and generic makers are required to have written procedures for the review, surveillance and reporting of adverse drug information, and any “serious and unexpected” drug experiences to the FDA.¹²⁵ Information obtained from any source, foreign or domestic, or any type of post-marketing study or

¹¹⁸ Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.
¹¹⁹ Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.
¹²³ Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.
¹²⁴ Boyd, supra note 65 at 1535.
¹²⁵ 21 C.F.R. § 312.32(c)(1)(i).
investigation must be reviewed. Both brand-name and generic manufacturers must comply with postmarking reports by submitting an annual report to the FDA including a summary of information that may affect the drug’s safety, effectiveness, or labeling, as well as a description of the actions taken in response to the new information and proposed revisions to the safety labels.

The Supreme Court ruling in *PLIVA* sparked the concern that generic labels are not sufficient to warn consumers of the risks associated with medications. Public policy favors informing health care practitioners and patients of prescription medication safety information. The public will benefit as a result of manufacturers updating drug safety labels in response to newly acquired safety information. Allison Zieve, head of the litigation group at Public Citizen, commented “[n]o drug is safe in all situations. A drug is safe when used in accordance with labeling that accurately reflects the known risks. The sooner generic drug companies are allowed to make safety updates, the better for public health.” The public is harmed when a regulatory delay allows a safety gap and when relevant information is not readily available to the affected parties. The ability to update safety information will ensures that patients have the most recent and reliable information about their medications, and can make an informed choice on whether to take a prescribed drug.

The proposed amendments to current FDA regulation will permit generic drug makers to update product labeling to “reflect data obtained through post-market[ing] surveillance.” Although the proposed amendment does not require generic manufactures to conduct new clinical tests, it will allow the manufacturers to inexpensively update labels when adverse information is received and investigated, while still keeping prices lower than brand-name

---

126 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, *supra* note 30.
127 Id.
130 Silverman, *FDA Delays Final Rule on Allowing Generic Drug Makers to Update Labels, supra* note 128.
131 Silverman, *FDA Delays Final Rule on Allowing Generic Drug Makers to Update Labels, supra* note 128.
Some argue prices will increase due to the liability generic drug makers would face. However, proponents believe generic drug makers will not face an increase in litigation because lawsuits would be less likely to occur when generic drugs are able to update safety information, preventing injury from occurring altogether. The FDA states the proposed regulation will “provide incentive to generic drug companies to actively participate with the FDA in ensuring the timeliness, accuracy and completeness of drug safety labeling.”

Lawmakers believe that “[t]his proposal will help equip health care providers and consumers who depend on generic drugs with the best possible information to avoid adverse outcomes.” The public will benefit because both brand-name and generic drug manufacturers will have the obligation to give doctors and patients the information necessary to avoid injuries. Through this amendment, the FDA will not only be able to preserve the principal of “sameness” between brand-name and generic drugs, but will also allow patients to have better information about a drug’s potential risks and benefits, regardless of the manufacturer.

Many opponents of the regulations claim that the time period where labels may differ will cause confusion and lead to over-warning. However, under the current regulations, when a brand-name drug has a safety label update, it can take several months before generic drug manufacturers update their labels with the new warnings. Also, brand-name drugs have possessed the ability to update their own safety labels for over thirty years, and there has never been a problem with over-warning of safety information.

133 See generally note 41.
135 Id.
138 Id.
139 Id.
140 Zieve, supra note 114.
141 Zieve, supra note 114.
142 Zieve, supra note 114.
The confusion concerning the temporary differences in brand and generic labels will be outweighed by the public health benefits. Dr. Woodcock, opined: “It is expected that a valid safety concern regarding a generic drug product also would generally warrant submission of a supplement for change to the labeling by the application holder for the corresponding brand drug, as well as other generic drug application holders.” Therefore, it can be assumed when new safety information is acquired, all manufacturers will apply to change the label, reducing the amount of differing labels even before the FDA has approved the change. Further, the FDA will maintain a website tracking CBE-0 supplements, so health care providers and patients will have access to the newest changes and updates. Once the FDA approves a CBE-0 supplement, it will continue to be posted on the site, and a thirty-day timeframe will be established for drug manufacturers to submit a CBE-0 supplement conforming to the label change. This will cut down the amount of time that differing labels will be available on the market. Under the FDCA, the FDA is authorized to “require and, if necessary [order] labeling changes if the FDA becomes aware of new safety information that the FDA believes should be included in the labeling of the drug.” Therefore, the FDA can implement a rule allowing generic drugs to independently update warning labels, ensuring the newest warnings are available to consumers, regardless of whether they take brand-name or generic medication.

Senator Henry Waxman, co-author of the 1984 Hatch-Waxman Act, argued that allowing generic drugs to update their labels will ease customers’ concerns about the danger of taking generic drugs because they will be aware of the latest risks and safety information. Waxman further argued that it will aid in preventing consumers from believing generic drugs are not as safe as brand-name drugs because generics will have more incentive to warn consumers about safety issues, and will be able to get the information out to consumers. Generic drug manufacturers have already proven that

---

143 See Zieve, supra note 114.
144 Woodcock, supra note 15.
146 Woodcock, supra note 15, at 7, 9.
148 Tim Devaney, FDA Raises Safety Measure for Generic Drugs. THE HILL, April 1,
Generic drugs are equally as safe as the brand-name counterpart and the FDA has agreed.\textsuperscript{149} Gary Beuhler, Director of the FDA's office of Generic Drugs argued “[m]ost people believe that if something costs more, it has to be better quality. In the case of generic drugs, this is not true . . . [t]he standards for quality are the same for brand-name and generic products.”\textsuperscript{150}

Alison Zieve of Public Citizen has argued, “[a]s generic drugs’ market shares increase, brand-name drugs lose incentive to engage in safety monitoring.”\textsuperscript{151} Zieve further argued “[t]he FDA cannot monitor all post-approval data by itself, drug safety is threatened when the regulatory and common-law incentives designed to motivate manufacturer diligence weaken with shifting control of market share.”\textsuperscript{152} Because the generic drug has the majority of the market share, they will probably receive the most reports concerning risks and adverse experiences using the drug.\textsuperscript{153} Generic manufacturers therefore may be in a better position to update product safety labels because they serve a larger amount of the population.\textsuperscript{154} Under the current system, the generic manufacturers cannot update safety information until the brand-name takes action.\textsuperscript{155}

Allowing generic drug manufacturers to independently update product safety labels in light of newly acquired safety information will be a great benefit to public health by increasing patient safety and awareness, while keeping costs and confusion at a minimum.

B. Generic Drugs Will Continue to be an Affordable Alternative to Brand-Name Prescriptions

Generic drugs are more affordable because manufacturers do
not need to spend money on costly clinical trials. Even if generics had more responsibility under the proposed regulation, the savings would still be apparent. The proposed rule would assist in keeping liability costs down by preventing injuries from occurring in the first place through efficient safety label updates. Currently, generic drugs are shielded from liability because they cannot update their labels. If a generic drug maker becomes aware of a risk, they cannot change safety labels, unless the brand-name does so.

Critics of the proposed regulation fear that allowing generic drug makers to update their product safety labels will open them up to failure-to-warn lawsuits. However, if the injuries had never occurred, there would be no lawsuit. Allison Zieve of Public Citizen testified in front of the House of Representatives Subcommittee on Health:

Because immunizing the companies from liability does not make the injured patients’ costs go away. The medical expenses and lost wages from lost work time still exist; they are carried by the patients, health insurers, and taxpayers, through Medicare or Medicaid. Because the proposed rule will give generic manufacturers the tools and incentive to update safety labeling, any costs of the rule should be offset by cost savings—savings in medical care for the patients who will not be injured because physicians and patients are armed with updated labeling about safety risks.

Critics also fear that generic drug manufacturers may over-warn to avoid liability. However, proponents have noted since the ruling in Wyeth there has not been a surge in CBE-0 supplements to update brand-name labels, therefore there should not be a worry for over warning by generic drug makers.

According to the FDA, “the main reason generic drug companies can market their drugs at lower prices is that they don’t face the same development costs as brand-name companies.” Generic drugs are approved through an expedited process, and are permitted to skip costly clinical trials provided that the drug is the “same” and the “bioequivalent” of its brand-name counterpart.
The proposed regulation does not place any new requirements for generic drugs to undergo separate clinical trials and testing, therefore the costs to consumers should remain low.164 Allison Zieve stated “[g]eneric competition [also] helps keep the cost of drugs down . . . it also encourages the research based drug companies to keep finding new and better medicines that have patent protection.”165

An estimate published by the consulting firm Matrix Global Advisors stated the proposed rule would lead to approximately a five percent annual increase in spending on generic drugs.166 The FDA has examined the economic impacts of the proposed regulation and has determined:

the proposed rule would only impose new burdens on small generic drug manufacturers who submit CBE-0 supplements for safety-related labeling changes. The FDA believes the impact will not be significant due to the low cost of submission, and the uncertainty of the amount of supplements that may be filed.167

C. Allowing Generic Drug Makers to Update Product Safety Labels will Provide a Means for Generic Drugs which no Longer have a Brand-name Counterpart to Make Safety Updates

The FDA estimates there is approximately 420 drugs that are sold only in the generic form.168 The Generic Pharmaceuticals Association states that number is even larger, estimating that about 45% of generic drugs have no brand-name counterpart.169 There is a gap in the current regulatory system for generic drugs whose brand-name drug counterpart is no longer sold on the market. Since a brand-name drug is only permitted to update safety warnings on product labels, the generic drugs that no longer have a brand-name counterpart are left without a means of updating safety label information.170 Currently, there are no clear and efficient methods to disseminate information to health care providers, and the public, about newly discovered safety risks.171

164 See generally, Devany, supra note 148.
165 Devany, supra note 148
166 Carlson, supra note 10.
167 Wolfman, supra note 23.
168 Zieve, supra note 114.
169 Zieve, supra note 114.
170 Boyd, supra note 65.
171 Carlson, supra note 10.
This is concerning because serious drug risks may not be identified until after the generic drug enters the market, and several generic drugs no longer have a corresponding brand-name drug on the market.\(^{172}\) Without a corresponding brand-name drug, there are no available resources to conduct ongoing investigations as to the safety of the drug.\(^{173}\) Therefore, drugs that are only available in generic form are not continuously monitored or investigated, and there is no way to update the drug’s label if new safety information comes to their attention.

IV. CONCLUSION

The FDA has acknowledged the growth of the generic pharmaceutical industry, and its impact on the United States’ health industry. Today, generic drugs fill almost 90% of all pharmaceuticals in the United States, yet consume only 27% of total drug spending, resulting in huge savings to American consumers every year.\(^ {174}\)

The Hatch-Waxman Act of 1984 allowed generic drugs to be approved through an abbreviated process, provided the generic drug was the “same” in ingredients, dosage, and administration, and was the “bioequivalent” of the brand-name drug.\(^ {175}\) The enactment led to a greater number of generic drug approvals, and millions of dollars of savings in drug costs to American consumers.\(^ {176}\)

The FDASIA and GDUFA were enacted in 2012 in response to the emerging generic drug industry.\(^ {177}\) The GDUFA was enacted to increase safety and accessibility of generic drugs, and provide transparency by inspecting all generic drug facilities.\(^ {178}\) The Act was designed to expedite the approval process of generic drugs, and as a result, cut down the backlog of pending approvals.\(^ {179}\) As generic

\(^{172}\) Carlson, supra note 10.
\(^{173}\) Carlson, supra note 10.
\(^{174}\) Neas, supra note 3.
\(^{175}\) Wolfman, supra note 23.
\(^{176}\) Generic Drug User Fee Act Program Performance Goals and Procedures, supra note 43.
\(^{178}\) Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, supra note 30.
drugs continue to take an increasing amount of market share, the government has responded by imposing similar burdens and benefits on generics as brand-name drugs through GDUFA. Allowing generic drugs to file CBE-0 changes and update labels would conform to this emerging trend.

The proposed regulation to permit generic drug manufacturers to update their safety labels without FDA approval, and independent of the brand-name drug’s label will result in an increase of safety information that is beneficial to public health. Patients and physicians will be up to date with the newest safety information concerning generic drugs, which are used by the majority of Americans today.

Although this may create temporary differences between generic and brand-name drug labels, it will increase patient safety overall. Allowing generic drug manufacturers to independently update safety labels will also encourage them to monitor and research the safety of marketed drugs; while also having the possibility of increasing the quality of the drugs being manufactured by creating liability for generic products.

Updating the FDA’s current regulations will also create an opportunity for generic drugs that no longer have a brand-name counterpart to keep patients up to date on the newest safety information, and provide a consistent method for updating safety labels for all drugs and prescriptions in the United States.